（文章来源：证券日报） 证券日报网讯 1月13日，康龙化成发布公告称，公司预计2025年营业收入1387162.56万元至1423989.89 万元，同比增长13%至16%；归属于上市公司股东的净利润161401.57万元至168574.98万元，同比下降 6%至10%。 ...

Group 1 - The core point of the article is that Lianchi Hospital Group Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with China Galaxy International as the exclusive sponsor [1] Group 2 - The application for listing indicates the company's intention to raise capital through public markets, which may suggest growth plans or expansion strategies [1] - The involvement of China Galaxy International as the exclusive sponsor highlights the importance of strategic partnerships in the IPO process [1]

康龙化成：全年净利润初步数据16.1亿元人民币至16.9亿元人民币。 ...

康龙化成（300759）(300759.SZ)发布2025年年度业绩预告，预计2025年度归属于上市公司股东的净利 润16.14亿元至16.86亿元，同比下降6%–10%。 经公司初步测算，2025年度归属于上市公司股东的非经常性损益约为人民币11,000万元至人民币13,000 万元，主要包括计入当期损益的政府补助、其他非流动金融资产公允价值变动收益及投资的中低风险银 行理财产品相关损益等。 ...

按业绩预告中位值测算，2025年第四季度，公司营业收入同比增长 14.79%、归属于上市公司股东的扣 除非经常性损益后的净利润同比增长 54.09%、经调整的非《国际财务报告准则》下归属于上市公司股 东的净利润同比增长16.36%。 智通财经APP讯，康龙化成(03759)公布，该集团预期2025年实现营收约138.72亿-142.4亿元，同比增长 13%-16%;归属于上市公司股东的净利润约16.14亿-16.86亿元，同比下降6%-10%;扣非净利约15.07 亿-15.62亿元，同比增长36%-41%;经调整的非《国际财务报告准则》下归属于上市公司股东的净利润约 17.675亿-18.48亿元，同比增长10%-15%。 ...

1、商务部：自2026年1月14日起，对原产于美国和韩国的进口太阳能级多晶硅继续征收反倾销税 商务部公告，自2026年1月14日起，对原产于美国和韩国的进口太阳能级多晶硅继续征收反倾销 税，实施期限为5年。 据美国媒体报道，美国国务院发布紧急安全警示，要求美国公民"立即离开伊朗，制定不依赖美国 政府协助的离境计划；如无法离境，请留在住所或其他安全建筑内，并储备食物、水、药品及其他生活 必需品；避免参加任何示威活动，保持低调，注意周围环境；关注当地媒体获取最新消息，并随时调整 计划；保持手机电量充足，与家人朋友保持联系，及时告知情况。（CCTV国际时讯） 4、1月13日午间涨停分析 创业板指半日跌0.83%，AI医疗概念持续活跃，商业航天概念集体退潮。锋龙股份13连板，一图看 懂>> 5、外交部：中方维护全球关键矿产产业链稳定和安全的立场没有变化 1月13日，外交部发言人毛宁主持例行记者会。对于七国集团（G7）财长涉华言论，毛宁表示，中 方维护全球关键矿产产业链稳定和安全的立场没有变化，我们也认为各方都有着责任这样做。（央视新 闻） 6、国投白银LOF：1月14日开市起至当日10:30停牌 国投瑞银基金管理有限 ...

Core Viewpoint - The company is actively monitoring the application and development of cutting-edge technologies, including brain-computer interfaces, in the healthcare sector, and is committed to a cautious and pragmatic layout based on clinical value and long-term strategic direction [1] Group 1: Company Developments - The company has established a comprehensive management plan for Parkinson's disease treatment using brain-computer interfaces, covering preoperative screening, intraoperative implementation, postoperative monitoring, and rehabilitation [1] - The company's affiliated Yuncheng Hospital has successfully completed over 20 deep brain stimulation (DBS) surgeries, providing innovative treatment options for Parkinson's patients [1] Group 2: Technological Innovations - The company-managed Shanghai Yongci Rehabilitation Hospital has collaborated with Fourier to create a leading domestic rehabilitation robot IoT port [1] - The rehabilitation robot, as the core device of the IoT port, offers highly personalized rehabilitation services, enhances rehabilitation efficiency, and effectively optimizes the allocation of human resources for rehabilitation therapists [1] Group 3: Commitment to Transparency - The company adheres to an open and win-win ecological philosophy and will fulfill its information disclosure obligations in a timely manner according to legal regulations and supervisory requirements for any significant developments [1]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Tongce Medical (600763), indicating a slight increase in stock price and mixed capital flow on January 13, 2026 [1] - As of January 13, 2026, Tongce Medical's stock closed at 42.48 yuan, with a trading volume of 15.21 million shares and a total transaction value of 653 million yuan [1] - The capital flow data shows a net outflow of 12.39 million yuan from institutional investors, while retail investors experienced a net outflow of 4.51 million yuan, indicating varied investor sentiment [1] Group 2 - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, reflecting a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The third quarter of 2025 saw a single-quarter main revenue of 842 million yuan, with a net profit of 192 million yuan, both showing year-on-year increases of 2.34% and 2.31% respectively [2] - The company has a debt ratio of 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, alongside a gross profit margin of 41.69% [2] Group 3 - In the last 90 days, seven institutions have provided ratings for Tongce Medical, with four buy ratings and three hold ratings, and the average target price set at 5.29 billion yuan [2]

Core Viewpoint - The article discusses the recent fluctuations in the A-share market, highlighting the mixed sentiment among investors and the potential for continued volatility leading up to the Two Sessions in March [1][3]. Market Overview - On January 13, the three major indices in the A-share market collectively declined, with the Shanghai Composite Index down 0.64%, the Shenzhen Component down 1.37%, and the ChiNext down 1.96% [8]. - The total trading volume reached 36,991.09 billion yuan, an increase of 541.38 billion yuan from the previous day, setting a new historical record [8]. - Over 3,700 stocks in the market experienced declines, with 77 stocks hitting the daily limit up [8]. Sector Performance - The medical services sector showed strength, with several stocks, including Nuo Si Ge and Pu Rui Si, hitting the daily limit up [8]. - The AI application sector experienced volatility, with stocks like Tianlong Group and Di'an Diagnosis also reaching the daily limit up [8]. - The commercial aerospace sector faced adjustments, with several stocks dropping over 10% [8]. Investment Trends - According to CITIC, the current market sentiment is high, but there are no signs of weakening indicators yet. The short-term outlook suggests a continued rotation among themes and small-cap stocks until the Two Sessions [3]. - The article notes that the expected incremental capital for 2026 is projected at 30,378.13 billion yuan, with various sources contributing to this growth, including household deposits and institutional asset reallocation [4]. Company Highlights - Three Transform Technology has been involved in providing gas turbine transformers for the U.S. Musk xAI supercomputing data center, indicating a growing demand in the energy sector [6]. - TCL Technology expects a net profit of 4.21 billion to 4.55 billion yuan for 2025, representing a year-on-year growth of 169% to 191% [17]. - Dazhu CNC anticipates a net profit of 785 million to 885 million yuan for 2025, driven by increased demand for AI server components [17]. Regulatory and Policy Updates - The Ministry of Commerce announced the continuation of anti-dumping duties on imported solar-grade polysilicon from the U.S. and South Korea, effective January 14, 2026, for a period of five years [13]. - The article mentions a strategic partnership between EndoQuest Robotics and NVIDIA to enhance surgical robotics with high-performance computing [14]. Capital Flow Insights - The net outflow of main funds reached 117.06 billion yuan, with the electronic sector experiencing the largest outflow [20]. - The article highlights the net inflow of funds into sectors such as media, pharmaceuticals, and non-ferrous metals, while sectors like electronics and defense saw significant outflows [20].

伴随着2025年年报披露的拉开序幕，热门赛道的核心公司业绩是否能持续支撑高估值，成为许多基本面投资者关注的焦点。 披露时间来看，业绩预告早于业绩快报，早于定期报告。以年报为例，①年度业绩预告于1月31日前披露，沪市、深市主板、创业板公司若出现净利润亏 损、扭亏为盈、净利润同比变动±50%以上、净资产为负（深市主板、创业板）必须强制披露；②业绩快报于2月底前披露，其中深市中小板、创业板公 司，若年报预约披露时间为3-4月，需强制发布年度业绩快报。沪市主板、深市主板公司可自愿披露，非强制；③年报正式披露介于1月-4月，其中3 月-4 月为集中披露期。 | | 25 年 1 月 | 25年２月 | 25年3月 | 25年4月 | | --- | --- | --- | --- | --- | | 2024 年报 业绩预告数量 | 2759 | ব | 32 | 75 | | 2024 年报 业绩快报数量 | 74 | 886 | 114 | 80 | | 2024 年报 定期报告数量 | | ટર | 964 | 4408 | 而从实务效果看，以Go-Goal每季度业绩超预期公司做成的组合看，2012年至今，业绩超 ...